Cancer Research Annual Meeting 2010  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 69, 1485, February 15, 2009. Published Online First January 27, 2009;
doi: 10.1158/0008-5472.CAN-08-3659
© 2009 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0008-5472.CAN-08-3659v1
69/4/1485    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Catalano, A.
Right arrow Articles by Procopio, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Catalano, A.
Right arrow Articles by Procopio, A.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

The Plexin-A1 Receptor Activates Vascular Endothelial Growth Factor-Receptor 2 and Nuclear Factor-{kappa}B to Mediate Survival and Anchorage-Independent Growth of Malignant Mesothelioma Cells

Alfonso Catalano1, Raffaella Lazzarini1,2, Silvia Di Nuzzo1, Silvia Orciari1 and Antonio Procopio1,2

1 Department of Molecular Pathology and Innovative Therapies, Marche University; 2 Center of Cytology, Research Department, Italian National Research Centers on Aging (INRCA-IRCCS), Ancona, Italy

Requests for reprints: Alfonso Catalano, Dipartimento di Patologia Molecolare, Politecnica delle Marche, Via Tronto 10/A, 60100 Ancona, Italy. Phone: 39-0712206245; Fax: 39-0712206240; E-mail: a.catalano{at}univpm.it.

Key Words: plexin-A1 • Sema6D • semaphorins • malignant pleural mesothelioma

The semaphorins and their receptors, the neuropilins and the plexins, are constituents of a complex regulatory system that controls axonal guidance. Moreover, many types of tumor cells express various members of semaphorins and receptors, but the biological activities within tumor mass and the signal transduction mechanism(s) they use are largely unknown. Here, we show that in asbestos-related malignant pleural mesothelioma (MPM), Semaphorin-6D (Sema6D) and its receptor plexin-A1 are frequently expressed and trigger a prosurvival program that promotes anchorage-independent growth of MPM cells. Interestingly, the same response is also controlled by the tyrosine kinase receptors of vascular endothelial growth factor (VEGF) through a nuclear factor-{kappa}B (NF-{kappa}B)–dependent pathway. We found that in MPM cells, plexin-A1 and VEGF-receptor 2 (VEGF-R2) are associated in a complex. Moreover, the presence of Sema6D promotes the tyrosine phosphorylation of VEGF-R2 in a plexin-A1–dependent manner. This is necessary for basal and Sema6D-induced NF-{kappa}B transcriptional activity, and NF-{kappa}B mediates tumor cell survival. Expression of Sema6D and plexin-A1 is induced by asbestos fibers and overexpression of plexin-A1 in nonmalignant mesothelial cells inhibits cell death after asbestos exposure. This work identifies a new biological function of semaphorins in cancer cells and suggests the involvement of an undescribed survival pathway during MPM tumorigenesis. [Cancer Res 2009;69(4):1485–93]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.